Novo Nordisk pops 8% after Hims & Hers pulls copycat weight-loss pill

Novo Nordisk shares jumped 8% Monday after Hims & Hers said it will pull its copycat weight-loss pill off the market.

Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration had threatened legal action against Hims & Hers, which announced over the weekend it would not sell the pill.

"Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry," Hims & Hers posted on social media on Saturday.

"As a result, we have decided to stop offering access to this treatment. We remain committed to the millions of Americans who depend on us for access to safe, affordable, and personalized care."

This is a breaking news story. Please refresh for updates.